Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Arecor Reformulates Existing Drugs Rather Than Discovering New Ones — And Partners Are Paying For It

Arecor operates two complementary tracks: a proprietary clinical pipeline centred on next-generation insulins for pumps and automated insulin delivery systems, and a partnering engine applying Arestat to third-party molecules under formulation-development collaborations. Arestat is the intellectual heart — a proprietary formulation technology overcoming aggregation, …

Ishan Mudgal | 15 July 2026

AstraZeneca's Pipeline Just Delivered a Win and a Setback in the Same Month

AstraZeneca is headquartered in Cambridge, organised around four therapy areas: Oncology, Cardiovascular/Renal/Metabolism (CVRM), Respiratory & Immunology, and Rare Disease (built substantially on the 2021 Alexion acquisition). It's a FTSE 100 constituent under ticker AZN, with primary listing in London plus Nasdaq Stockholm; in February …

Ishan Mudgal | 15 July 2026

Avacta's Cancer Drug Cleared an FDA Hurdle — But Only With a Partner Will It Go Further

Following a multi-year restructuring, Avacta describes itself as a pure-play precision oncology company, developing tumour-activated cancer medicines. In March 2025 it sold Launch Diagnostics (a distribution business) for £12.9m, followed in August 2025 by agreeing to sell Coris Bioconcept SRL for roughly £2.2m including …

Ishan Mudgal | 15 July 2026

Genus's Gene-Edited Pig Cleared US and Canadian Regulators — Commercial Proof Is the Next Test

Genus develops and sells superior animal genetics, principally to pork, dairy and beef producers, allowing farmers to breed livestock that grow more efficiently, produce more milk or meat, and require fewer inputs. Genus PIC (Pig Improvement Company) supplies porcine genetics and is the larger …

Ishan Mudgal | 15 July 2026

Haleon Is Now Fully Independent — Here's Whether 'Resilient' Actually Means Risk-Free

Haleon makes and sells branded, largely over-the-counter products for everyday health — oral care, pain relief, vitamins and supplements, respiratory and digestive health, and therapeutic skin health. This is FMCG with a healthcare tilt, not a clinical-stage drug developer. Its 'power brands' include Advil, …

Ishan Mudgal | 15 July 2026

4basebio's Synthetic DNA Business Is Growing Fast — But So Are the Losses

4basebio manufactures synthetic DNA using an enzymatic, cell-free process — marketed as opDNA, and in compact form as hpDNA — for use in mRNA production, gene editing, viral vectors and DNA vaccines. It's also developing Hermes, a non-viral delivery platform pitched as an alternative …

Ishan Mudgal | 15 July 2026

Agronomics Trades at Half Its Own Stated Value — Here's What's In the Portfolio

Agronomics Limited is an investment company on AIM under ANIC (also traded in the US as AGNMF), co-founded by investor Jim Mellon, who chairs the board. It takes equity positions in early-stage businesses producing animal products without rearing or slaughtering animals. Crucially, it's a …

Ishan Mudgal | 15 July 2026

Allergy Therapeutics Won a Real German Approval — But Who's Actually In Control?

Founded in 1998 and headquartered on the English south coast, Allergy Therapeutics develops and sells allergen immunotherapy — treatments seeking to modify the underlying allergic response rather than just suppress symptoms. It markets across continental Europe, principally through German commercial arm Bencard Allergie. The …

Ishan Mudgal | 15 July 2026

Is Sareum Holdings PLC's Drug Pipeline Strong Enough to Drive Future Growth?

Sareum Holdings PLC is a UK-based biotechnology company focused on developing innovative small-molecule therapies for autoimmune diseases and cancer. Rather than generating revenue from commercial products, the company concentrates on advancing promising drug candidates through clinical development with the objective of creating value via …

Ishan Mudgal | 15 July 2026

Is Verici Dx PLC an Undervalued Healthcare Opportunity?

Verici Dx PLC is a biotechnology company focused on developing advanced diagnostic solutions designed to improve outcomes for organ transplant patients. The company specializes in molecular diagnostics that help clinicians assess transplant rejection risk and optimize patient management through precision medicine.

Ishan Mudgal | 15 July 2026
Support

Hi! How can we help you today?

Loading…